A modified cyclosporine enhances lentivector transduction ex vivo and in vivo by degrading IFITM3

Authors:
  • DADara Annett
    Dara Annett
  • KMKate L. Morling
    Kate L. Morling
  • BCBethan J. Critchley
    Bethan J. Critchley
  • BGBen Graham
    Ben Graham
  • VPValeria Pingitore
    Valeria Pingitore
  • TWThomas E. Whittaker
    Thomas E. Whittaker
  • NKNada Kurdi
    Nada Kurdi
  • JWJustin Warne
    Justin Warne
  • DLDiego León-Rico
    Diego León-Rico
  • NKNihansu Kuru
    Nihansu Kuru
  • STSara Toros
    Sara Toros
  • TNTasnim Nurullah
    Tasnim Nurullah

Abstract
Intrinsic innate immune barriers have evolved to suppress viral infection and can reduce effective gene delivery in gene therapy. We have developed BG147, a novel cyclosporine A analogue, optimised via structure-guided design to prevent inhibition of HIV cofactor Cyclophilin A and to specifically inhibit interferon-induced transmembrane proteins (IFITM1-3). BG147 enhances VSV-G pseudotyped lentiviral vector transduction ex vivo in hematopoietic stem and progenitor cells (HSPCs) and in in vivo ocular gene therapy of photoreceptor cells in mice. Upon BG147 treatment, IFITM proteins are mislocalised and degraded through lysosomal acidification-dependent pathways. IFITM3 levels functionally return in cells 96 h after BG147 washout. BG147 promises to transform ex vivo and in vivo eye gene therapies by transiently inhibiting intrinsic immune barriers mediated by IFITM proteins to enhance a wide range of protocols. One Sentence Summary: Modified cyclosporine, BG147, enhances lentivector gene therapy transduction, ex vivo in HSPC and in vivo in mouse photoreceptors, by degrading IFITM3.
Funding Information
  • Wellcome Trust (214344)
  • Wellcome Trust (220863)
  • Wellcome Trust (217112/Z/19/Z)
  • Rosetrees Trust (ID2020/100020)
  • UCL Biomedical Research Centre (BRC1191/III/101350)

This publication has 59 references indexed in Scilit: